In accordance with 21 CFR 314.53, this section includes patent information on Form FDA 3542a for patents that claim the drug substance, drug product, or method of use for LUXTURNA. The key patents related to voretigene neparvovec and its use in treating RPE65 mutation-associated retinal dystrophy, invented by Drs. Jean Bennett and Albert M. Maguire and assigned to the University of Pennsylvania, are licensed exclusively to Spark Therapeutics, Inc. A full list of relevant patents is provided.